Berbamine Hydrochloride: Potent NF-κB Inhibitor for Cancer Research

Executive Summary: Berbamine hydrochloride is a synthetic derivative of berberidis with demonstrated anticancer properties, notably as an inhibitor of the NF-κB signaling pathway (APExBIO). It exhibits cytotoxicity in leukemia (KU812) and hepatocellular carcinoma (HepG2) cell lines at IC₅₀ values of 5.83 μg/ml (24h) and 34.5 μM, respectively (Wang et al. 2024). The compound's solubility in DMSO, water, and ethanol enables diverse experimental setups. Its activity against the NF-κB pathway and potential utility in modulating ferroptosis resistance make it a promising tool for translational oncology research (Amyloid-b-peptide.com). Proper storage and handling parameters are critical to maintain compound integrity.

Biological Rationale

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling is central to cellular proliferation, inflammation, and apoptosis evasion in cancer. Dysregulation of NF-κB is implicated in tumorigenesis, therapy resistance, and chronic inflammation (Wang et al. 2024). Hepatocellular carcinoma (HCC) and leukemia frequently exhibit NF-κB hyperactivity, contributing to poor prognosis and resistance to apoptosis-inducing therapies. Recent advances have highlighted the METTL16-SENP3-LTF axis as a key modulator of ferroptosis resistance in HCC, with iron metabolism and cell death pathways intersecting NF-κB-driven oncogenic processes. Targeting NF-κB and related axes holds translational promise for overcoming tumor survival mechanisms (a77-01.com).

Mechanism of Action of Berbamine hydrochloride

Berbamine hydrochloride directly inhibits the NF-κB signaling pathway by blocking nuclear translocation and DNA-binding of NF-κB subunits, thereby suppressing transcription of anti-apoptotic and proliferation-related genes (2xtaqpc.com). This disruption sensitizes cancer cells to cell death, including ferroptosis, an iron-dependent form of regulated cell death. In HCC models, NF-κB inhibition may synergize with interventions targeting the METTL16-SENP3-LTF axis, reducing ferroptosis resistance and enhancing therapeutic responses (Wang et al. 2024). The molecular weight of the compound is 681.65 g/mol, and its chemical formula is C₃₇H₄₂Cl₂N₂O₆.

Evidence & Benchmarks

• Berbamine hydrochloride exhibits an IC₅₀ of 5.83 μg/ml (24h) in KU812 leukemia cells, measured via cytotoxicity assay (APExBIO).
• In HepG2 hepatocellular carcinoma cells, Berbamine hydrochloride shows an IC₅₀ of 34.5 μM, confirming its efficacy against solid tumor models (Wang et al. 2024).
• The compound inhibits NF-κB pathway activation, as evidenced by reduced nuclear localization and downstream gene expression (a77-01.com).
• Solubility: ≥68 mg/mL in DMSO, ≥10.68 mg/mL in water, and ≥4.57 mg/mL in ethanol, facilitating broad assay compatibility (APExBIO).
• Storage: Optimal stability is achieved at -20°C in a sealed, dry environment; solutions are not suitable for long-term storage (APExBIO).
• Recent studies implicate NF-κB and METTL16-SENP3-LTF axis interactions in ferroptosis resistance and tumorigenesis in HCC (Wang et al. 2024).

This article updates prior summaries (e.g., Amyloid-b-peptide.com) by providing new details on solubility and precise IC₅₀ values relevant for experimental planning.

Applications, Limits & Misconceptions

Berbamine hydrochloride is designed for in vitro and preclinical research applications targeting NF-κB signaling and ferroptosis modulation. It is suitable for cytotoxicity assays, pathway inhibition studies, and mechanistic investigations in leukemia and HCC models. The compound supports workflows probing the METTL16-SENP3-LTF axis, a newly identified determinant of ferroptosis resistance in hepatocellular carcinoma (Wang et al. 2024). For a broader discussion of translational implications and strategic deployment, see Cyclo-RGDFK.com; this article details updated molecular targets and solubility benchmarks.

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Berbamine hydrochloride is strictly for research; it is not FDA-approved for human therapy (APExBIO).
• Long-term solution storage reduces activity: Prepared solutions are chemically unstable and must be used immediately for reproducible results (APExBIO).
• Selectivity is cell-type dependent: Efficacy and IC₅₀ values may vary outside validated KU812 and HepG2 models (Wang et al. 2024).
• NF-κB is not the only pathway affected: Off-target effects may occur, particularly at high concentrations.
• Compound activity may be confounded by poor solubilization: Adhere to solvent recommendations to ensure full dissolution and bioavailability.

Workflow Integration & Parameters

APExBIO supplies Berbamine hydrochloride (SKU: N2471) as a solid, enabling flexible formulation. For in vitro studies, dissolve to ≥68 mg/mL in DMSO for concentrated stock solutions, or use water/ethanol per assay compatibility. Final working concentrations should be calibrated based on cell line sensitivity (e.g., 5.83 μg/ml for KU812, 34.5 μM for HepG2). Store the solid at -20°C in a sealed, desiccated container; avoid repeated freeze-thaw cycles. Prepared solutions should be freshly made before each experiment. For researchers targeting ferroptosis resistance, Berbamine hydrochloride can be combined with modulators of the METTL16-SENP3-LTF axis for mechanistic synergy (Wang et al. 2024).

This guidance extends the strategic perspectives in A77-01.com by specifying operational parameters and highlighting recent mechanistic insights.

Conclusion & Outlook

Berbamine hydrochloride, provided by APExBIO, is a robust tool for probing NF-κB signaling inhibition and ferroptosis resistance in challenging cancer models. Its validated cytotoxicity and solubility support high-confidence, reproducible research. As the METTL16-SENP3-LTF axis emerges as a key regulator of cell death in HCC, integrating Berbamine hydrochloride into preclinical workflows is poised to accelerate discovery and translational advances (Wang et al. 2024).